MARTINSRIED, Germany, Feb. 20, 2009 (GLOBE NEWSWIRE) -- MorphoSys AG (Frankfurt:MOR) (Prime Standard Segment, TecDAX) announced today the appointment of a new Head of Pre-clinical Development & Project Management. Dr. Ulrich Moebius joins MorphoSys from Medigene AG, a TecDAX listed German biopharmaceutical company. For the last nine years, he held the position of Head of Pre-clinical Development, where he was responsible for the company's preclinical activities in a range of development projects predominantly in cancer and contributed to the market approval of two medical therapies. Prior to his tenure at Medigene, he spent five years with the Deutsches Krebsforschungszentrum DKFZ, Heidelberg, the leading German biomedical research institute dedicated to cancer research and two years at the Dana-Farber Cancer Institute located in Boston, Massachusetts, USA. Dr. Moebius has a PhD in immunology from Johannes Gutenberg University Mainz and qualified as a professor in Immunology at the University of Heidelberg.
